April 2015, Volume 1, Issue 4

April 2015

Volume 1, Issue 4

This issue features a look at the ACA’s out-of-pocket limit, reports from the IOM’s Pediatric Oncology Workshop, tips for improving your presentations, and more.

Table of Contents

April 2015

Integrating Palliative Care in Hematology

Wednesday, April 1st, 2015
What are the goals of palliative care? Palliative care clinicians treat physical symptoms (pain- and non-pain-related) and also aim to alleviate psychological, social, and spiritual...

Don’t Just Do Something! Stand There.

Wednesday, April 1st, 2015
It’s the hardest thing in the world to do – or not do, as the case may be. Someone has just been diagnosed with cancer....

April 2015

Nominations for ASH Leadership Positions, and more

Wednesday, April 1st, 2015
Clinical Practitioners: Nominate Yourself or a Colleague for an ASH Leadership Position ASH members in good standing can nominate themselves or other members for leadership...

Mapping the Road to Progress in Lymphoma Research: An Update from the ASH Meeting...

Wednesday, April 1st, 2015
To review the state of science in lymphoma biology, the American Society of Hematology (ASH) organized the ASH Meeting on Lymphoma Biology in August...

April 2015

Pulling Back the Curtain: Steven L. Allen, MD

Wednesday, April 1st, 2015
What was your first job? Technically, my first job as a teenager was in the medical field – I helped install the first window air...

The ACA Out-of-Pocket Limit: Good and Bad News for Hematology Patients

Wednesday, April 1st, 2015
Although the act sets limits on the out-of-pocket expenses a patient might face, many costs associated with hematologic care may fall outside of the...

Stephan Moll, MD: As the Lathe Turns…

Wednesday, April 1st, 2015
What sparked your interest in woodturning? It happened by chance a few years ago: I have always enjoyed building and repairing things, including working with...

April 2015

Understanding Hemophilia

Wednesday, April 1st, 2015
A bleeding disorder is a condition in which a person tends to bleed longer (not faster) before a blood clot forms to stop the bleeding....

How would you treat a patient with Hodgkin lymphoma and bleomycin lung injury?

Wednesday, April 1st, 2015
This month, George P. Canellos, MD, advises on treatment options for a young patient with Hodgkin lymphoma and bleomycin lung injury.A 23-year-old male patient with...

The Do’s and Don’ts of Research Presentations

Wednesday, April 1st, 2015
There’s a basic formula for presentations of any kind: “Tell them what you are going to tell them; then tell them; and then tell...

April 2015

You’ve Gotten Blood on Your Clothes – What Do You Do Next?

Wednesday, April 1st, 2015
A survey of ASH Clinical News readers presents some interesting advice: (Happy April Fool’s Day!)

Is Carpet Thickness at Exhibitor Booths the Key to Drug Sales?

Wednesday, April 1st, 2015
Who knows why doctors prescribe the medications they do? Low adverse events? Long-term efficacy? Recent research has revealed that plush carpet at the exhibitor...

The Dead Sea Slideshows

Wednesday, April 1st, 2015
Recently uncovered slidescroll presentations from the 1282 A.D. ASH Annual Meeting reveal the year's biggest therapeutic breakthroughs in hematology. Spoiler alert: It was a big...
WIB_icon

Entospletinib Makes Its Mark in Chronic Lymphocytic Lymphoma

Wednesday, April 1st, 2015
Therapies that target B-cell receptor signaling kinases have made great strides in chronic lymphocytic lymphoma (CLL) and other B-cell malignancies. According to results from...

How Costly is Febrile Neutropenia in Patients with Metastatic Cancer?

Wednesday, April 1st, 2015
Febrile neutropenia (FN) is a frequent and often costly complication for patients with metastatic cancer receiving myelosuppressive chemotherapy. When patients develop FN, the likelihood...

Carfilzomib in Multiple Myeloma, New FDA App to Track Drug Shortages, and more

Wednesday, April 1st, 2015
Carfilzomib Granted Priority Review in Relapsed Multiple Myeloma The U.S. Food and Drug Administration granted priority review status to the supplemental new drug application for...
WIB_icon

Novel Agent Attacks the Cause of Vaso-Occlusive Crisis in Sickle Cell Disease

Wednesday, April 1st, 2015
Vaso-occlusive crisis (VOC) is a severely painful disease manifestation in adolescent and adult patients with sickle cell disease (SCD). Currently, treatment is limited to...

Ruxolitinib: Another Option for Polycythemia Vera Patients with Poor RESPONSE

Wednesday, April 1st, 2015
Patients with polycythemia vera who do not respond well to hydroxyurea may have another promising treatment option, according to results from the RESPONSE trial. A...

Newer TKIs Versus Imatinib in CML-CP Patients

Wednesday, April 1st, 2015
With the emergence of second-generation tyrosine kinase inhibitors (TKIs), more choices than ever exist for treating patients with chronic-phase chronic myeloid leukemia (CML-CP). However,...
WIB_icon

Ibrutinib-Chemoimmunotherapy Combo Adds to CLL Therapy

Wednesday, April 1st, 2015
In chronic lymphocytic leukemia (CLL), combining two effective treatments enhances their clinical activity, according to early study results published recently in Blood. Treatment-naive CLL patients...

Red or White Blood Cell? Donut Ask a Cop!

Wednesday, April 1st, 2015
A joint poll conducted by the Association of American Medical Colleges and Dunkin' Donuts found that: (Happy April Fool's Day!)

April 2015

IOM/ACS Pediatric Oncology Workshop Highlights Survivorship Issues

Wednesday, April 1st, 2015
On March 9-10, the Institute of Medicine’s (IOM’s) National Cancer Policy Forum (NCPF) and the American Cancer Society (ACS) sponsored a workshop on Comprehensive...

SHARE